PharmaSGP Holding SE
XETRA:PSG
PharmaSGP Holding SE
Interest Income Expense
PharmaSGP Holding SE
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Interest Income Expense
-€2.7m
|
CAGR 3-Years
-203%
|
CAGR 5-Years
-221%
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Interest Income Expense
-$1.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Interest Income Expense
-€2.2B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
|
Merck KGaA
XETRA:MRK
|
Interest Income Expense
-€74m
|
CAGR 3-Years
34%
|
CAGR 5-Years
28%
|
CAGR 10-Years
10%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Interest Income Expense
€30.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Interest Income Expense
-€64.3m
|
CAGR 3-Years
-99%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
PharmaSGP Holding SE
Glance View
PharmaSGP Holding SE engages in the sale and marketing of non-prescription drugs, chemical-free over-the-counter painkillers, as well as herbal medicines. The company is headquartered in Graefelfing, Bayern. The company went IPO on 2020-06-19. The firm produces and develops non-chemical and over-the-counter drugs and other healthcare products.
See Also
What is PharmaSGP Holding SE's Interest Income Expense?
Interest Income Expense
-2.7m
EUR
Based on the financial report for Dec 31, 2023, PharmaSGP Holding SE's Interest Income Expense amounts to -2.7m EUR.
What is PharmaSGP Holding SE's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-221%
Over the last year, the Interest Income Expense growth was -46%. The average annual Interest Income Expense growth rates for PharmaSGP Holding SE have been -203% over the past three years , -221% over the past five years .
You don't have any saved screeners yet